Literature DB >> 22196079

The re-emergence of measles in developed countries: time to develop the next-generation measles vaccines?

Gregory A Poland, Robert M Jacobson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22196079      PMCID： PMC3905323          DOI： 10.1016/j.vaccine.2011.11.085

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


× No keyword cloud information.
  11 in total

1.  Measles eradication still a long way off.

Authors:  S Davey
Journal:  Bull World Health Organ       Date:  2001       Impact factor: 9.408

2.  Taking the initiative.

Authors: 
Journal:  Lancet Infect Dis       Date:  2005-12       Impact factor: 25.071

3.  Notes from the field: Measles outbreak--Indiana, June-July 2011.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2011-09-02       Impact factor: 17.586

Review 4.  Biological feasibility of measles eradication.

Authors:  William J Moss; Peter Strebel
Journal:  J Infect Dis       Date:  2011-07       Impact factor: 5.226

5.  Notes from the field: Measles outbreak--Hennepin County, Minnesota, February-March 2011.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2011-04-08       Impact factor: 17.586

Review 6.  Measles and rubella in the United States.

Authors:  H W Hethcote
Journal:  Am J Epidemiol       Date:  1983-01       Impact factor: 4.897

7.  A large observational study to concurrently assess persistence of measles specific B-cell and T-cell immunity in individuals following two doses of MMR vaccine.

Authors:  Iana H Haralambieva; Inna G Ovsyannikova; Megan O'Byrne; V Shane Pankratz; Robert M Jacobson; Gregory A Poland
Journal:  Vaccine       Date:  2011-05-01       Impact factor: 3.641

8.  Global measles elimination efforts: the significance of measles elimination in the United States.

Authors:  Peter M Strebel; Ana-Maria Henao-Restrepo; Edward Hoekstra; Jean-Marc Olive; Mark J Papania; Stephen L Cochi
Journal:  J Infect Dis       Date:  2004-05-01       Impact factor: 5.226

Review 9.  Failure to reach the goal of measles elimination. Apparent paradox of measles infections in immunized persons.

Authors:  G A Poland; R M Jacobson
Journal:  Arch Intern Med       Date:  1994-08-22

Review 10.  Measles control and the prospect of eradication.

Authors:  W J Moss
Journal:  Curr Top Microbiol Immunol       Date:  2009       Impact factor: 4.291
View more
  17 in total

1.  In Vivo Efficacy of Measles Virus Fusion Protein-Derived Peptides Is Modulated by the Properties of Self-Assembly and Membrane Residence.

Authors:  T N Figueira; L M Palermo; A S Veiga; D Huey; C A Alabi; N C Santos; J C Welsch; C Mathieu; B Horvat; S Niewiesk; A Moscona; M A R B Castanho; M Porotto
Journal:  J Virol       Date:  2016-12-16       Impact factor: 5.103

Review 2.  Development of next-generation respiratory virus vaccines through targeted modifications to viral immunomodulatory genes.

Authors:  Christopher C Stobart; Martin L Moore
Journal:  Expert Rev Vaccines       Date:  2015-10-05       Impact factor: 5.217

3.  Genetically defined race, but not sex, is associated with higher humoral and cellular immune responses to measles vaccination.

Authors:  Emily A Voigt; Inna G Ovsyannikova; Iana H Haralambieva; Richard B Kennedy; Beth R Larrabee; Daniel J Schaid; Gregory A Poland
Journal:  Vaccine       Date:  2016-08-30       Impact factor: 3.641

4.  Prevention of measles virus infection by intranasal delivery of fusion inhibitor peptides.

Authors:  C Mathieu; D Huey; E Jurgens; J C Welsch; I DeVito; A Talekar; B Horvat; S Niewiesk; A Moscona; M Porotto
Journal:  J Virol       Date:  2014-11-05       Impact factor: 5.103

Review 5.  The genetic basis for interindividual immune response variation to measles vaccine: new understanding and new vaccine approaches.

Authors:  Iana H Haralambieva; Inna G Ovsyannikova; V Shane Pankratz; Richard B Kennedy; Robert M Jacobson; Gregory A Poland
Journal:  Expert Rev Vaccines       Date:  2013-01       Impact factor: 5.217

Review 6.  Variability in Humoral Immunity to Measles Vaccine: New Developments.

Authors:  Iana H Haralambieva; Richard B Kennedy; Inna G Ovsyannikova; Jennifer A Whitaker; Gregory A Poland
Journal:  Trends Mol Med       Date:  2015-11-18       Impact factor: 11.951

7.  Genome-wide associations of CD46 and IFI44L genetic variants with neutralizing antibody response to measles vaccine.

Authors:  Iana H Haralambieva; Inna G Ovsyannikova; Richard B Kennedy; Beth R Larrabee; Michael T Zimmermann; Diane E Grill; Daniel J Schaid; Gregory A Poland
Journal:  Hum Genet       Date:  2017-03-13       Impact factor: 5.881

8.  Cost effectiveness of a web-based decision aid for parents deciding about MMR vaccination: a three-arm cluster randomised controlled trial in primary care.

Authors:  Sandy Tubeuf; Richard Edlin; Swati Shourie; Francine M Cheater; Hilary Bekker; Cath Jackson
Journal:  Br J Gen Pract       Date:  2014-08       Impact factor: 5.386

9.  The epidemiological and clinical characteristics of measles in Wenzhou, China, 2000-2010.

Authors:  Z W Xu; Y P Chen; M J Yang; W C Li; Q Liu; J Lin
Journal:  Epidemiol Infect       Date:  2013-03-18       Impact factor: 4.434

10.  Profiling of measles-specific humoral immunity in individuals following two doses of MMR vaccine using proteome microarrays.

Authors:  Iana H Haralambieva; Whitney L Simon; Richard B Kennedy; Inna G Ovsyannikova; Nathaniel D Warner; Diane E Grill; Gregory A Poland
Journal:  Viruses       Date:  2015-03-10       Impact factor: 5.048
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.